Drug Trial Radar · NCT05601440
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
484
Planned (sponsor's estimate)
Start
Jun 13, 2023
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- First posted
- Nov 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study
Conditions
- Breast Cancer
Interventions
RP-6306Drug
Dose and schedule will be assigned at enrolment
GemcitabineDrug
Dose and schedule will be assigned at enrolment
ObservationOther
Monitoring arm
NiraparibDrug
Dose and schedule will be assigned at enrolment
FulvestrantDrug
Dose and schedule will be assigned at enrolment
RP-3500Drug
Dose and schedule will be assigned at enrolment
CFI-402257Drug
Dose and schedule will be assigned at enrolment
CFI-400945Drug
Dose and schedule will be assigned at enrolment
Sacituzumab govitecanDrug
Dose and schedule will be assigned at enrolment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate whether biomarker selection improves outcomes as assessed by RECIST 1.1 for overall response rateTime frame: 5 years
- Evaluate whether biomarker selection improves outcomes as assessed by RECIST 1.1 for clinical benefit rateTime frame: 5 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
BCCA - Kelowna
Kelowna, British Columbia, Canada · Recruiting
BCCA - Vancouver
Vancouver, British Columbia, Canada · Recruiting
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada · Recruiting
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada · Recruiting
Kingston Health Sciences Centre
Kingston, Ontario, Canada · Recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
Odette Cancer Centre
Toronto, Ontario, Canada · Suspended
University Health Network
Toronto, Ontario, Canada · Recruiting
The Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.